your partner in preclinical research

Latest Posts

> 2016 Jan

Season’s Greetings and Best Wishes!

Read more

> 2015 Jun


Urosphere is pleased to announce another step in its commitment to the highest quality standards. Urosphere obtained the certification of its Quality Management System (QMS) ISO 9001: 2008 provided by Lloyd's Register Quality Assurance (LRQA), a world’s leading provider of certifications.  “Today, we become the first CRO specialized in preclinical pharmacology in the field of urogenital pathologies. We provide to our customers an internationally recognized certification of its QMS not only for the scientific side of our activity but also for the whole organization.” said Dr. Philippe LLUEL, Chief Executive Officer.

Demonstrating a real commitment to service quality, Urosphere applies on a daily bases the following principles:
- To provide customers the competency of our staff and high level of expertise,
- To listen and to adapt to specific needs,
- To guarantee a perfect traceability of our data,
- To become a privileged partner. Click here to see our certificate of approval: ISO 9001 certification

Read more

> 2015 Mar

ORGANOCAN : UROsphere collaborative project.

Colorectal cancers and those of the urological sphere (prostate and bladder) are among the five most common cancers. A chronic inflammatory condition predisposes to the appearance of some of these cancers (colon, prostate). Today, the available experimental models poorly simulate the biological reality and function of the body, which makes it particularly difficult to develop new drugs. The objective of the Organocan 2 project is to develop cell models in 3-dimensional (organoid) of colon, bladder and prostate representing the molecular and cellular complexity of human organs. This tool will implement additional efficiency filter to improve the selection of drug candidates, but also to develop personalized medicine tools (therapeutic and diagnostic tests) and to understand the fundamental mechanisms of carcinogenesis and inflammation. This project is based on the complementarity of four partners: an innovative SME specialized in the field of urology (UROsphere), an Inserm team (Team Dr. N. Vergnolle U1043), a pharmaceutical company (Pierre Fabre) and the Toulouse University Hospital (CHU Toulouse).

Read more

> 2014 Jun

UROsphere attended to the Association Française des Sciences et Techniques de l’Animal de Laboratoire (AFSTAL) annual meeting, Toulouse, France, from 4 to 6 June 2014.

            Dr. Murielle Méen presented an oral communication on Wednesday June 4th entitled: UROsphere, experimental platform for urogenital disorders: Focus on interstitial cystitis.

Read more

> 2014 May

UROsphere will present its latest scientific developments in preclinical sex health models at the annual meeting of the American Urological Association, to be held in Orlando, Florida, May 16-21, 2014.

    Dr Julien Allard will present two moderated posters (session Sexual Function/Dysfunction/Andrology: Basic Research II, room W307) on Monday, May 19th, 08:00-10:00 AM:   Poster 1: Dapoxetine inhibits erectile responses to stimulation of cavernous nerve in rats: a new hypothesis for its effects on ejaculation. Poster 2: Mice with the null leptin receptor as a translational model of type II diabetes-induced erectile dysfunction: in vivo assessment and the effect of sildenafil.   Dr. Allard will be available throughout the entire meeting for discussions on these translational models.

Read more